Publications by authors named "S Goland"
Background: Aortic valve stenosis of any degree is associated with poor outcomes.
Objectives: The authors aimed to develop a risk prediction model for aortic stenosis (AS) prognosis using machine learning techniques.
Methods: A prognostic algorithm was developed using an AS registry of 10,407 patients undergoing echocardiography between 2008 and 2020.
Article Synopsis
- Steroidal mineralocorticoid receptor antagonists help patients with heart failure and reduced ejection fraction, but their effectiveness in those with mildly reduced or preserved ejection fraction is unclear, indicating a need for further research on finerenone.
- In a double-blind study, patients with heart failure (ejection fraction 40% or greater) were assigned to receive either finerenone or a placebo to assess its impact on heart failure events and cardiovascular death.
- Results showed that finerenone led to fewer worsening heart failure events and a lower overall rate of primary outcome events compared to placebo, although it also carried a higher risk of hyperkalemia.
Article Synopsis
- Peripartum cardiomyopathy (PPCM) is a serious heart condition affecting mothers, and this study investigates the use of bromocriptine, a potential treatment alongside standard care, to see if it improves maternal outcomes.
- The study analyzed data from the EORP PPCM registry, comparing outcomes of 85 patients treated with bromocriptine to 409 patients receiving standard treatment, revealing that bromocriptine was linked to better maternal health outcomes.
- Results showed a significant reduction in adverse outcomes for the bromocriptine group (22% had complications) compared to the standard care group (33%), suggesting that bromocriptine may be an effective option for treating PPCM.
Aims: To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS-HF trial is comparing the effects of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF.
Methods And Results: Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.